Literature DB >> 12501976

Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly.

L M Fatti1, M Scacchi, A I Pincelli, E Lavezzi, F Cavagnini.   

Abstract

Respiratory disorders are common and important complications in acromegaly. Patients suffering from acromegaly display a 1.6-3.3 fold increase in mortality rate, which is due to respiratory disorders in 25% of cases. In these patients, mortality for lung disease is 2-3 fold higher than in the general population. Every portion of the respiratory system may be involved. Deformities of facial bones, edema and hypertrophy of the mucosae and pharyngeal and laryngeal cartilages, enlargement of the tongue and inspiratory collapse of the hypopharinx, all may contribute to respiratory alterations. Nasal polyps, "hormonal rhinitis", changes of the voice and snoring are common occurrences. Though rarely, a laryngocele may ensue. Pneumomegaly is frequently observed and, as suggested by functional studies, might be due to an increased number rather than volume of the alveoli. An obstructive respiratory syndrome caused by mucosal thickening of the upper airways and bronchi is observed in 25% of female and 70% of male patients. The sleep apnea syndrome (SAS) affects 60-70% of acromegalic patients. SAS may be of obstructive, central or mixed type. Obstructive SAS is the prevailing form in acromegaly. It is due to intermittent obstruction of upper airways with preserved activity of the respiratory center, as testified by the remarkable thoracic and abdominal respiratory efforts. The pathogenesis of the central type of SAS is more complex. Narrowing of the upper airways may induce reflex inhibition of the respiratory center. Moreover, increased GH levels and, possibly, defects in the somatostatinergic pathways, may increase the ventilatory response of the respiratory center to carbon dioxide, thereby leading to respiratory arrest. In the mixed type of SAS, the phenomena underlying the other two forms coexist. Oxygen desaturation concomitant with the apneic episodes accounts for the frequent nocturnal wakening and diurnal drowsiness. Among the clinical correlates of SAS, arterial hypertension is of particular interest due to the close correlation existing between the two disorders. Sleep deprivation related to SAS seems per se to favor the appearance of hypertension. Moreover, short lasting hypoxemia may induce prolonged elevations of blood pressure, mediated by decreased endothelial generation of nitric oxide. Thus, since cardiovascular events are the main cause of mortality in patients with acromegaly, it is reasonable to hypothesize that SAS is involved in the reduced life span of these patients.

Entities:  

Mesh:

Year:  2001        PMID: 12501976     DOI: 10.1023/a:1020702631793

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  35 in total

1.  Pulmonary function in acromegaly.

Authors:  C C Evans; L J Hipkin; G M Murray
Journal:  Thorax       Date:  1977-06       Impact factor: 9.139

Review 2.  ABC of sleep disorders. The sleep apnoea/hypopnoea syndrome and snoring.

Authors:  N J Douglas
Journal:  BMJ       Date:  1993-04-17

Review 3.  Sleep apnea syndrome: recent advances.

Authors:  C Guilleminault; J Cummiskey; W C Dement
Journal:  Adv Intern Med       Date:  1980

4.  Fixity of vocal cords and laryngocele in acromegaly.

Authors:  S Motta; D Ferone; A Colao; B Merola; G Motta; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

5.  Left ventricular dysfunction, pulmonary hypertension, obesity, and sleep apnea.

Authors:  R P Blankfield; A A Tapolyai; S J Zyzanski
Journal:  Sleep Breath       Date:  2001-06       Impact factor: 2.816

6.  Undiagnosed sleep apnea in patients with essential hypertension.

Authors:  E C Fletcher; R D DeBehnke; M S Lovoi; A B Gorin
Journal:  Ann Intern Med       Date:  1985-08       Impact factor: 25.391

7.  Sleep apnea in acromegaly.

Authors:  R R Grunstein; K Y Ho; C E Sullivan
Journal:  Ann Intern Med       Date:  1991-10-01       Impact factor: 25.391

Review 8.  Epidemiology of obstructive sleep apnea.

Authors:  E A Bresnitz; R Goldberg; R M Kosinski
Journal:  Epidemiol Rev       Date:  1994       Impact factor: 6.222

9.  Acromegalic pneumonomegaly: lung growth in the adult.

Authors:  J S Brody; A B Fisher; A Gocmen; A B DuBois
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

Review 10.  Epidemiology of obstructive sleep apnea syndrome.

Authors:  M Partinen; T Telakivi
Journal:  Sleep       Date:  1992-12       Impact factor: 5.849

View more
  17 in total

1.  Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters.

Authors:  L Vannucci; P Luciani; E Gagliardi; S Paiano; R Duranti; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2012-07-09       Impact factor: 4.256

2.  Sleep apnea syndrome in acromegalic patients: Can morphological evaluation guide us to optimize treatment?

Authors:  Ana M Ramos-Levi; Mónica Marazuela
Journal:  Endocrine       Date:  2015-10-30       Impact factor: 3.633

3.  Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity.

Authors:  J Roemmler; B Gutt; R Fischer; S Vay; A Wiesmeth; M Bidlingmaier; J Schopohl; M Angstwurm
Journal:  Sleep Breath       Date:  2012-01-13       Impact factor: 2.816

4.  The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013.

Authors:  Gudrun Thuridur Hoskuldsdottir; Sigridur Bara Fjalldal; Helga Agusta Sigurjonsdottir
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

5.  Morphological study of upper airways and long-term follow-up of obstructive sleep apnea syndrome in acromegalic patients.

Authors:  Cinzia Castellani; Giuseppe Francia; Luca Dalle Carbonare; Marcello Ferrari; Elena Viva; Roberto Cerini; Alessandro Zaccarella; Lorenzo Trevisiol; Maria Vittoria Davi'
Journal:  Endocrine       Date:  2015-06-21       Impact factor: 3.633

6.  IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea.

Authors:  Daniel A Heinrich; Claudia Reinholz; Maximilian Bauer; Amanda Tufman; Richard Frohner; Jochen Schopohl; Martin Bidlingmaier; Robert P Kosilek; Martin Reincke; Harald J Schneider
Journal:  Endocrine       Date:  2018-01-31       Impact factor: 3.633

7.  The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels.

Authors:  Xiaopeng Guo; Yumo Zhao; Man Wang; Lu Gao; Zihao Wang; Zhuhua Zhang; Bing Xing
Journal:  Endocrine       Date:  2018-06-21       Impact factor: 3.633

Review 8.  Clinical, quality of life, and economic value of acromegaly disease control.

Authors:  A Ben-Shlomo; M C Sheppard; J M Stephens; S Pulgar; S Melmed
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

9.  Clinical manifestations and diagnosis of acromegaly.

Authors:  Gloria Lugo; Lara Pena; Fernando Cordido
Journal:  Int J Endocrinol       Date:  2012-02-01       Impact factor: 3.257

10.  Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients.

Authors:  Mark L Hartman; Rong Xu; Brenda J Crowe; Leslie L Robison; Eva Marie Erfurth; David L Kleinberg; Alan G Zimmermann; Whitney W Woodmansee; Gordon B Cutler; John J Chipman; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2013-01-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.